T. Rowe Price Associates
MPLT

T. Rowe Price Associates’s MapLight Therapeutics MPLT Stock Holding History

T. Rowe Price Associates’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51M Buy
1,422,935
+1,310,227
+1,162% +$37.7M 0.01% 882
2026
Q1 		$2.29M Buy
+112,708
New +$2.02M ﹤0.01% 1767

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

T. Rowe Price Associates's MPLT Position: Q2 2026 in Review

T. Rowe Price Associates increased its MapLight Therapeutics (MPLT) stake by 1,162% in Q2 2026, buying an estimated $37.7M and bringing the position to 1,422,935 shares worth $51M. The position accounts for 0.01% of the portfolio, ranked #882.

T. Rowe Price Associates first reported a position in MPLT in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • T. Rowe Price Associates held 1,422,935 shares of MapLight Therapeutics worth $51M as of Q2 2026.
  • T. Rowe Price Associates bought 1,310,227 MapLight Therapeutics shares in Q2 2026, an estimated $37.7M.
  • MapLight Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #882 holding.
  • T. Rowe Price Associates first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.